SimBioSys Raises $15 Million Series A to Develop the Future of Precision Cancer Care

SimBioSys, closed a $15 Million Series A funding round on October 26th.

The company’s novel, simulation-based, precision medicine platform, TumorScope, enables individualized treatment planning for cancer patients.

This Series A was co-led by Genoa Ventures and Northpond Ventures, with participation from AV8 Ventures, Heritage Medical Group, and Mayo Clinic.

Read the full press release.